97 related articles for article (PubMed ID: 27084669)
1. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
2. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U; Sroczynski G; Rossol S; Wasem J; Ravens-Sieberer U; Kurth BM; Manns MP; McHutchison JG; Wong JB; ;
Gut; 2003 Mar; 52(3):425-32. PubMed ID: 12584228
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY
Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Gissel C; Götz G; Mahlich J; Repp H
BMC Infect Dis; 2015 Jul; 15():297. PubMed ID: 26223310
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; Main J; Thomas H
Gut; 2006 Sep; 55(9):1332-8. PubMed ID: 15994216
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Lu Y; Jin X; Duan CA; Chang F
PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
[TBL] [Abstract][Full Text] [Related]
11. Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
Solomon SS; Sulkowski MS; Amrose P; Srikrishnan AK; McFall AM; Ramasamy B; Kumar MS; Anand S; Thomas DL; Mehta SH
J Viral Hepat; 2018 Jan; 25(1):37-46. PubMed ID: 28719029
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
[TBL] [Abstract][Full Text] [Related]
13. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S; Cipriano LE; Holodniy M; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2012 Feb; 156(4):279-90. PubMed ID: 22351713
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors.
Arshad M; Wei F; Nelsen DA
Antivir Ther; 2015; 20(8):827-33. PubMed ID: 26555064
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
Stahmeyer JT; Rossol S; Liersch S; Guerra I; Krauth C
PLoS One; 2017; 12(1):e0169401. PubMed ID: 28046099
[TBL] [Abstract][Full Text] [Related]
17. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
Rattanavipapong W; Anothaisintawee T; Teerawattananon Y
PLoS One; 2018; 13(2):e0193112. PubMed ID: 29466415
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Rein DB; Wittenborn JS; Smith BD; Liffmann DK; Ward JW
Clin Infect Dis; 2015 Jul; 61(2):157-68. PubMed ID: 25778747
[TBL] [Abstract][Full Text] [Related]
19. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
Pfeil AM; Reich O; Guerra IM; Cure S; Negro F; Müllhaupt B; Lavanchy D; Schwenkglenks M
PLoS One; 2015; 10(5):e0126984. PubMed ID: 25974722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
